TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-10-29 reports Item 5.02 event(s) regarding departure of director(s) or officer(s) and/or compensatory arrangements, with period of report dated 2026-10-27. The filing contains no disclosed dollar amounts, share counts, counterparty names, or specific details of changes—only the structural notification that such event(s) occurred.
Why this rating
Standard 8-K disclosure of officer/director event. No quantitative details provided; nature and magnitude of any change unknown from this summary. Routine executive governance filing.
Extracted items
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.